Lung Cancer

Dr. Jessica Donington provides an overview of key ongoing clinical trials of systemic adjuvant therapy in early non-small cell lung cancer.

An expert surgeon explains the role patients have in adjuvant therapy selection for early non-small cell lung cancer.

Patients with lung cancer whose symptoms were managed by automated alerts to their care team through an electronic system after surgery had fewer post-surgical complications than patients who received standard care.

Dr. Martin Dietrich reviews some factors to consider when selecting an adjuvant therapy for early non-small cell lung cancer.

Jessica Donington, MD, MSCR, describes how she discusses adjuvant therapy with patients diagnosed with early non-small cell lung cancer.

Patients who limit alcohol intake during their cancer treatment may experience several health benefits, according to physicians from Tampa Bay Radiation Oncology.

Side effects from cancer treatment with immunotherapy, which may include vitiligo and certain rashes, may point to who will respond better to the treatment, although more research is needed to determine how much weight to put on these data.

From the lung cancer death of “Seinfeld” actress Kathryn Kates to a patient with cancer who broke a rowing world record, here’s what’s happening in the cancer landscape this week.

An expert oncologist details the design, outcomes, and clinical implications of the IMpower010 trial.

Dr. Jessica Donington explains how the results of the ADAURA trial changed the treatment algorithm in the adjuvant setting in early non-small cell lung cancer.

Researchers plan to enroll 60 patients in the first-in-human phase 1 clinical trial to assess the safety and preliminary clinical activity of an anti-CD39 monoclonal antibody to treat advanced solid tumors.

After promising phase 3 clinical trial results, the FDA will consider Libtayo for approval to treat patients with advanced non-small cell lung cancer, regardless of PD-L1 status.

A new study to evaluate the accuracy of a blood test for detecting lung cancer in high-risk adults has enrolled its first participant with plans to enroll thousands more.

Martin Dietrich, MD, PhD, describes the toxicity profiles of chemotherapy agents used in the adjuvant setting in early non-small cell lung cancer.

Two experts detail the use of adjuvant therapy, including chemotherapy, in treating early non-small cell lung cancer.

While robotic navigational bronchoscopy is an exciting advancement in diagnosing and staging lung cancer, the procedure does come with some risks and factors to consider, explained one expert.

In an interim analysis from a phase 3 trial of Keytruda, the use of the immunotherapy drug was associated with significantly improved disease-free survival in patients with non-small cell lung cancer.

Dr. Martin Dietrich explains the role of molecular testing in early non-small cell lung cancer.

Martin Dietrich, MD, PhD, and Jessica Donington, MD, MSCR, provide an overview on early non-small cell lung cancer and the available treatment options.

Certain allergy medications like Zyrtec and Claritin may be the key for more patients to tolerate immunotherapy for several cancer types.

Angela Criswell, director of quality screening and program initiatives at GO2 Foundation for Lung Cancer, discusses early detection and screening for lung cancer.

Daniel Saez, treatment and trials navigator at the GO2 Foundation for Lung Cancer, discusses biomarker testing and precision medicine in lung cancer.

Susan Smedley, national manager of community fundraising and endurance events at GO2 Foundation for Lung Cancer, offers resources for patients with lung cancer and their loved ones, as well as ways to get involved in the community.

Susan Smedley, national manager of community fundraising and endurance events at GO2 Foundation for Lung Cancer, discusses quality of life in lung cancer, and ways patients can communicate preferences to their health care providers.

The Food and Drug Administration will offer guidance and expedited review to CLN-081, a novel drug that is promising for the treatment of EGFR exon 20-mutated non-small cell lung cancer.